en · de · es · fr · pt
tb-500-notes.peptides6908.com › Data › Identification And Molecular Background — Research Overview

Identification And Molecular Background — Research Overview

By Editorial Desk · published 2026-04-19 · last reviewed 2026-06-03 · Data

actin-binding motif comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.

Identification and Molecular Background

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

Identity and Physical Form

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

Tb-500 at a glance

PropertyValueNotes
Generic designationSynthetic thymosin beta-4 N-terminal fragmentPeptide nomenclature varies by supplier
Peptide lengthApproximately 17 amino acid residuesReported length sometimes differs between sources
N-terminal modificationAcetyl groupAffects mass and chromatographic behaviour
Compound classSmall synthetic peptideNot a small-molecule drug
Common synonymsTB4 fragment; thymosin beta-4 fragmentNaming is inconsistent in popular media

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Related pages on this site

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Reference notes

== Structure == Optimer ligands are composed of single-stranded DNA or RNA polymers. These nucleic acid molecules can exhibit cognate base-pairing to produce sections of double-stranded DNA or RNA within the Optimer molecules. Optimer ligands form secondary and tertiary structures with compatible internal base-pairing at specific portions of the ligand where possible according to the specific sequence. As not all of the bases in the Optimer sequence will be compatible for internal double-stranded pairing, single-stranded loop and bulge regions will remain in the secondary and tertiary structures, where hydrogen bond acceptor and donor groups are exposed and available to interact with the selected target for target engagement and target binding. The Optimer library that is screened for specific binders consists of 1014 sequences that will form different variable sequence-dependent structures. The wide diversity in this library enables target binding to a range of different molecules. Optimer molecules can bind crevices and exposed epitopes on protein and cellular targets and can wrap around small molecule targets. This enables an increased target range compared to traditional antibody technology that has limitations in accurately binding small molecule targets. As Optimer technology stems from aptamers, Optimer ligands have the ability to operate as reversible structural switches, changing their structure when binding their target molecule.

In other countries, such as Australia and the UK, the operation is commonly performed with the person undergoing a general anaesthetic. All cases require a careful follow-up with an eye doctor (ophthalmologist or optometrist) for a number of years. Frequently, vision is greatly improved after the surgery, but even if the actual visual acuity does not improve, because the cornea is a more normal shape after the healing is completed, people can more easily be fitted with corrective lenses. Complications of corneal transplants are mostly related to vascularization of the corneal tissue and rejection of the donor cornea. Vision loss is very rare, though difficult-to-correct vision is possible. When rejection is severe, repeat transplants are often attempted, and are frequently successful. Keratoconus will not normally reoccur in the transplanted cornea; incidences of this have been observed, but are usually attributed to incomplete excision of the original cornea or inadequate screening of the donor tissue. The long-term outlook for corneal transplants performed for keratoconus is usually favorable once the initial healing period is completed and a few years have elapsed without problems. One way of reducing the risk of rejection is to use a technique called deep anterior lamellar keratoplasty (DALK). In a DALK graft, only the outermost epithelium and the main bulk of the cornea, the stroma, are replaced; the person's rearmost endothelium layer and the Descemet's membrane are left, giving some additional structural integrity to the postgraft cornea.

63Ni, with a half-life of 100.1 years, is useful in krytron devices as a beta particle (high-speed electron) emitter to make ionization by the keep-alive electrode more reliable. It is being investigated as a power source for betavoltaic batteries. Around 27% of all nickel production is used for engineering, 10% for building and construction, 14% for tubular products, 20% for metal goods, 14% for transport, 11% for electronic goods, and 5% for other uses. In 2025, QuesTek Innovations and Stoke Space developed a nickel-based superalloy for additive manufacturing and extreme high-pressure, high-temperature oxygen environments. Its characteristics allow the material to be used for fully reusable spacecraft launch systems, it can withstand the full-flow staged combustion rocket engine Zenith. Raney nickel is widely used for hydrogenation of unsaturated oils to make margarine, and substandard margarine and leftover oil may contain nickel as a contaminant. Forte et al. found that type 2 diabetic patients have 0.89 ng/mL of Ni in the blood relative to 0.77 ng/mL in control subjects. Nickel titanium is an alloy of roughly equal atomic percentages of its constituent metals which exhibits two closely related and unique properties: the shape memory effect and superelasticity.

This basic structure was not touched by the Abbott, Turnbull and Morrison governments, although wages and standards continued to decline through lack of enforcement, growing casualization, and hostile judicial decisions. With the Albanese government, a series of reforms, such as the Fair Work Legislation Amendment (Closing Loopholes) Bill, aimed to raise protection, since Australian labour rights remained significantly below European and wealthier countries' standards. This includes the lack of a restored system for sectoral collective bargaining, weak protection for collective action, and absence of rights for workers to elect directors on boards of enterprises, outside isolated examples in universities or the Australian Broadcasting Corporation, 25 per cent of people on "casual" contracts, and stagnating real wages.

Sources: en.wikipedia.org

Reference notes

== History == Planet Half-Life ran from April 27, 1999 to August 13, 2012. Since then, it had undergone numerous format changes, both in content and aesthetic. The following is a timeline of major changes and other events.

Intracrines play a crucial role in maintaining stem cell populations and guiding their differentiation into specialized cell types. Many stem cell regulatory proteins, including vascular endothelial growth factor (VEGF), high-mobility group protein B1 (HMGB1), and homeodomain transcription factors such as Pax6 and Oct3/4, operate through intracrine mechanisms. These factors establish intracellular feedback loops that sustain differentiation programs, ensuring that once a stem cell commits to a particular lineage, the developmental process continues even after the external signal is removed. For instance, VEGF, a well-known angiogenic factor, is also an intracrine that promotes the survival and differentiation of hematopoietic stem cells. In VEGF-deficient cells, survival and colony formation are impaired, but these defects can be rescued by restoring intracellular VEGF levels, highlighting the necessity of intracrine VEGF in stem cell regulation. Similarly, the homeodomain transcription factor Pdx-1 can be internalized by target cells, where it upregulates its own synthesis and drives pancreatic duct cells toward an insulin-producing phenotype, demonstrating the ability of intracrines to induce cell fate changes.

== Reception == John Dickson Carr, a writer of locked-room mysteries, has his detective Dr. Gideon Fell declare this the "best detective tale ever written", in his novel The Hollow Man (1935). Agatha Christie praised The Mystery of the Yellow Room through the mouthpiece of her detective Hercule Poirot in her 1963 novel The Clocks:

==== Steatosis ==== Hepatotoxicity may manifest as triglyceride accumulation, which leads to either small-droplet (microvesicular) or large-droplet (macrovesicular) fatty liver. There is a separate type of steatosis by which phospholipid accumulation leads to a pattern similar to the diseases with inherited phospholipid metabolism defects (e.g., Tay–Sachs disease)

Receiving a red card (red card suspensions could be extended for serious offenses). Receiving two yellow cards in the tournament. This yellow card count was reset after the completion of the group stage and again after the quarterfinals. Resets did not apply to suspensions; a player whose yellow card count reached two in the match immediately before a reset was still suspended for the next match. During qualification for the World Cup, Cristiano Ronaldo was sent off for violent conduct in Portugal's penultimate match against the Republic of Ireland, with such an offense typically resulting in a ban of at least two matches. Ronaldo was handed a three-match ban, though the final two matches of the ban were suspended for a one-year probationary period, making him eligible to appear in Portugal's opening World Cup match. On May 8, 2026, the Bureau of the FIFA Council amended the tournament regulations so that pending one- or two-match suspensions resulting from red cards for two yellow cards, denying an obvious goal-scoring opportunity, or serious foul play during qualification would no longer be carried forward to the final competition. This exempted Argentina's Nicolás Otamendi, Ecuador's Moisés Caicedo, and Qatar's Tarek Salman from serving their qualifying-round suspensions during the tournament, with the bans to instead be served in a subsequent competition. During the round of 32, United States player Folarin Balogun was sent off, and was expected to be banned for the forthcoming round of 16 game against Belgium. Following lobbying from U.S.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 chemically?

It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.

Where does the name come from?

The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Network